Stocksigma LogoStocksigma Logo

Curis Lifesciences Reports Zero Deviation in IPO Proceeds Utilization as of Sep'26

Curis Lifesciences Limited reported nil deviation in the utilization of funds raised via its SME IPO for the half-year ended 30th Sep'26

Curis Lifesciences Reports Zero Deviation in IPO Proceeds Utilization as of Sep'26

Curis Lifesciences Ltd · Others (Uncategorized) · 11 Nov 2026, 9:39 pm

Curis Lifesciences Reports Zero Deviation in IPO Proceeds Utilization as of Sep'26 Curis Lifesciences Limited reported nil deviation in the utilization of funds raised via its SME IPO for the half-year ended 30th Sep'26. Out of the total ₹27.52 crore raised across 21.50 lakh equity shares at ₹128 each, the company has deployed ₹22.95 crore, leaving ₹5.37 crore unutilized. Key deployments include full utilization of ₹11.25 crore for working capital, ₹3.39 crore of ₹3.62 crore allocated for storage facility capex, ₹1.82 crore for debt repayment, and ₹2.89 crore toward general corporate purposes.

Original exchange filing (PDF)

More announcements from Curis Lifesciences Ltd

All Curis Lifesciences Ltd announcements